JAK2 and pulmonary arterial hypertension: These results not only provide novel insight into the pathogenesis underlying PAH, but also demonstrate evidence that blockade of JAK2 could be a viable approach to inhibit PASMC proliferation, which may have great potential for the treatment of PAH in clinical settings.